MHRA approves new single-dose injection device for the highest dose of Wegovy®▼ (semaglutide injection 7.2 mg once weekly dose)

·         The newly approved device delivers a pre‑set 7.2 mg once weekly maintenance dose of semaglutide in a single injection. Previously, the 7.2 mg dose was administered by taking three 2.4 mg injections together once weekly.

Gatwick, UK, 14 April 2026. Novo Nordisk today announces that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new single‑dose injection device for Wegovy^®▼ (semaglutide injection) 7.2 mg for use in the UK.

The newly approved device delivers a pre‑set 7.2 mg once weekly maintenance dose of semaglutide in a single injection. Previously, the 7.2 mg dose was administered by taking three 2.4 mg injections together once weekly.¹

The single‑dose device contains an automatic dosing mechanism with a built-in needle, which is enclosed within a needle cover and locks after use.

Novo Nordisk is working with healthcare partners and providers to support the introduction of the Wegovy^® 7.2 mg single‑dose device in the UK. Stock of the single dose device is expected in the UK in 4-6 weeks.

The new single dose device delivers one pre-set 7.2mg dose in one weekly injection demonstrating a mean weight loss of up to 20.7% (23.39 kg/ 51.58lbs /3st 9.6lbs) vs placebo in addition to diet and exercise,¹ with approximately a third of adult participants living with obesity achieving a weight loss of 25% (28.25 kg/ 62.28 lbs/ 4st 6.2lbs) after 72 weeks.²

Obesity is a complex, chronic disease³ affecting around 15 million people in the UK⁴ with 71% of adults in the UK projected to be living with obesity or overweight by 2040, if trends continue.⁵ The condition requires long-term management and tailored treatment options.⁶ The introduction of new treatment options further enhances a patient-centred approach to obesity management.

“The approval of this new single‑dose device provides an additional administration option for people in the UK who are prescribed the 7.2 mg once weekly maintenance dose of Wegovy^®. We welcome the MHRA’s decision and will continue to work with healthcare professionals and partners to support its introduction in line with local prescribing arrangements,” said Sebnem Avsar Tuna, UK General Manager, Novo Nordisk UK.